HIV PREP MEDICATION

Risks & Side Effect

In 2020, about 25% of the 1.2

million people for whom PrEP
is recommended will be given
it, up from only about 3% in
2015. (Young, 2021)

（HIV symbol- The Red Ribbon)

For adults and teenagers

You must be HIV-1 negative to start using PrEp medications.
You must get tested to make sure that you do not already have
HIV-1 infection.
Do not receive HIV-1 PrEP medications unless you are
confirmed to be HIV-1 negative.

Symptoms of HIV-1 infection

Tiredness Fever
Joint or Muscle Aches Headache
Rash Vomiting
Groin Night sweats

(Henrard et al., 1995)

PrEp medication may cause

serious side effects including:

Allergic reactions
Liver problem
Depression or mood changes
(Beymer et al., 2019) (Injectable HIV PrEp)

Call your healthcare provider or get medical help

right away if you have any of the above symptoms!

While you are receiving HIV-1 PrEP

medications:

Use a latex or polyurethane condom

(Latex or Polyurethane Condom)
to avoid getting sexually transmitted
diseases.
You must stay HIV-1 negative to
keep receiving HIV-1 PrEP
medications.
(Parikh & Mellors, 2022)

You are encouraged to report negative side effects of

prescription drugs to the FDA. Please Visit
www.fda.gov/medwatch, or call 1-800-FDA-1088.

 Citation
Young, C. A. (2021). FDA approves first once-monthly injectable drug regimen
for adults with HIV. Pharmacy Today, 27(3), 15.
https://doi.org/10.1016/j.ptdy.2021.02.007

Henrard, D. R., Daar, E., Farzadegan, H., Clark, S. J., Phillips, J., Shaw, G. M., &
Busch, M. P. (1995). Virologic and immunologic characterization of
symptomatic and asymptomatic primary HIV-1 infection. Journal of Acquired
Immune Deficiency Syndromes & Human Retrovirology, 9(3).
https://doi.org/10.1097/00042560-199507000-00013

Beymer, M. R., Holloway, I. W., Pulsipher, C., & Landovitz, R. J. (2019). Current
and future prep medications and modalities: On-demand, injectables, and
topicals. Current HIV/AIDS Reports, 16(4), 349–358.
https://doi.org/10.1007/s11904-019-00450-9

Parikh, U. M., & Mellors, J. W. (2022). How could HIV-1 drug resistance impact
preexposure prophylaxis for HIV prevention? Current Opinion in HIV and
AIDS, 17(4), 213–221. https://doi.org/10.1097/coh.0000000000000746